[{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"9 Meters Biopharma, Inc. Doses the First Patients in Phase 1b\/2a Clinical Trial in Short Bowel Syndrome","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"NM-002","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"9 Meters Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"9 Meters Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Genome & Company","pharmaFlowCategory":"D","amount":"$26.5 million","upfrontCash":"Undisclosed","newsHeadline":"Scioto Biosciences Receives Series B Investment from Genome & Company","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Series B Financing","leadProduct":"SB-121","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Scioto Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Scioto Biosciences \/ Genome & Company","highestDevelopmentStatusID":"7","companyTruncated":"Scioto Biosciences \/ Genome & Company"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Randomized Controlled Study Using Direct Injection of Remestemcel-L Into Inflamed Gut of Patients with Crohn\u2019s Disease AND Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Cleveland Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Mesoblast \/ Cleveland Clinic"},{"orgOrder":0,"company":"Parexel Biotech","sponsor":"Tiziana Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tiziana Life Sciences Announces Collaboration with Parexel Biotech to Conduct Phase 1b\/2 Clinical Trial in Patients with Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Parexel Biotech","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Parexel Biotech \/ Tiziana Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Parexel Biotech \/ Tiziana Life Sciences"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","amount":"$229.0 million","upfrontCash":"Undisclosed","newsHeadline":"Azurrx Biopharma Announces Acquisition of First Wave Bio and Its Proprietary Niclosamide Formulations Targeting Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0.23000000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ AzurRx","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ AzurRx"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"NB1000S","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Novome Biotechnologies","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Novome Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Novome Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"First Wave BioPharma, Inc. Announces Closing of $9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Public Offering","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave BioPharma Announces Poster Presentation at the 2022 Digestive Disease Week (DDW) Conference","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Tencent","pharmaFlowCategory":"D","amount":"$43.5 million","upfrontCash":"Undisclosed","newsHeadline":"Novome Biotechnologies Raises $43.5 Million Series B Financing to Advance its Pipeline of Therapeutically Engineered Microbes","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Series B Financing","leadProduct":"NB1000S","moa":"Oxalate","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Novome Biotechnologies","amount2":0.040000000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Novome Biotechnologies \/ Tencent","highestDevelopmentStatusID":"7","companyTruncated":"Novome Biotechnologies \/ Tencent"},{"orgOrder":0,"company":"ExeGi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ExeGi Pharma Announces Clearance of Investigational New Drug (IND) Application for EXE-346 a Live Biotherapeutic Biologic Drug","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"EXE-346","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"ExeGi","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ExeGi \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ExeGi \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"Niclosamide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"First Wave BioPharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ExeGi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ExeGi Pharma Announces First Patient Enrollment in the PROF Trial of EXE-346","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"EXE-346","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"ExeGi","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ExeGi \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ExeGi \/ Not Applicable"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Trial of EP-104GI","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eupraxia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Not Applicable"}]